PolyPeptide Group AG
PPGN
Company Profile
Business description
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
Contact
Neuhofstrasse 24
Baar
Zug6340
CHET: +41 435020580
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
1,366
Stocks News & Analysis
stocks
Apple earnings: Strong performance overpowers headwinds, and we raise our FVE
Our view of Apple shares.
stocks
Coles is winning the supermarket wars but is Woollies the better long-term opportunity?
Our view after first quarter sales updates.
stocks
Microsoft earnings: Strong, including Azure, but overall guidance is in line
We think Microsoft stock is moderately undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,182.50 | 24.00 | 0.26% |
| CAC 40 | 8,137.86 | 16.79 | 0.21% |
| DAX 40 | 24,218.92 | 260.62 | 1.09% |
| Dow JONES (US) | 47,562.87 | 40.75 | 0.09% |
| FTSE 100 | 9,731.58 | 14.33 | 0.15% |
| HKSE | 26,158.36 | 251.71 | 0.97% |
| NASDAQ | 23,724.96 | 143.81 | 0.61% |
| Nikkei 225 | 52,411.34 | 1,085.73 | 2.12% |
| NZX 50 Index | 13,556.30 | 7.98 | 0.06% |
| S&P 500 | 6,840.20 | 17.86 | 0.26% |
| S&P/ASX 200 | 8,894.80 | 36.20 | 0.41% |
| SSE Composite Index | 3,976.52 | 21.73 | 0.55% |